A major medical breakthrough in the global fight against hepatitis B has emerged, offering fresh hope that millions of patients may one day be liberated from lifelong medication regimens. Recent global clinical trials involving a novel experimental drug named Bepirovirsen have demonstrated remarkable results, achieving what medical experts define as a "functional cure" for a subset of patients. However, top liver specialists note that while this scientific leap represents the biggest advancement in nearly two decades, India’s primary hurdle remains the staggering population of undiagnosed carriers who remain completely unaware of their infection status.Global Clinical Trials and the Promise of BepirovirsenThe Phase 3 clinical trial data, published in the prestigious New England Journal of Medicine, evaluated 1,834 patients across 29 countries. The findings revealed that approximately 19% of patients who received Bepirovirsen alongside standard antiviral therapy achieved a functional cure—meaning the hepatitis B virus remained completely undetectable in their bodies even six months after stopping all medication. Unlike conventional antivirals that merely suppress viral activity and require continuous, often lifelong usage, Bepirovirsen targets the virus at an early stage of its life cycle, sharply reducing viral protein production and allowing the body's immune system to regain control.India’s Ground Realities: Silent Infections and Screening GapsMarking World Hepatitis Day, leading Indian hepatologists highlighted the immense public health challenge facing the country, where an estimated 35 million people live with chronic hepatitis B. According to Dr. S.K. Sarin, Director of the Institute of Liver and Biliary Sciences (ILBS), while inexpensive antiviral medications are accessible through government programs, fewer than 1 million patients receive treatment due to a severe lack of testing and awareness. Dr. Anil Arora, Chairman of the Institute of Liver, Gastroenterology and Pancreato-Biliary Sciences at Sir Ganga Ram Hospital, emphasized that achieving a functional cure is vital because it dramatically reduces the long-term risk of severe complications like liver cirrhosis and liver cancer.Who Benefits and the Continued Importance of VaccinationMedical experts have clarified that Bepirovirsen is not an immediate universal cure for every patient; initial estimates indicate it is most effective for individuals whose infections are already partially managed with low viral loads. Furthermore, specialists strongly stress that the new drug is not a substitute for prevention. Universal vaccination for newborns, rigorous screening of high-risk groups such as healthcare workers and dialysis patients, and timely testing for family members of infected individuals remain the ultimate frontline strategy for eradicating hepatitis B.
Around the web
